الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 118 |  |  |
| | | from | 118 | | |
Abstract
Chronic HCV infection affect host glucose and lipid metabolism. The virus induces hypocholesterolemia, insulin resistance (IR), diabetes, atherosclerosis and steatosis (Moucari et al., 2008).
This work aimed to determine the effects of treatment with DAAs on serum lipids (total cholesterol, low and high density cholesterol, triglycerides, ox LDL) and Insulin Resistance (IR) in chronic HCV patients.
To investigate the effect of new direct acting antiviral drugs sofosbuvir/daclatasvir (SOF/DAC) on lipid metabolism and insulin resistance eighty sex chronic hepatitis c genotype 4 were included. Lipid profile changes and IR were analyzed at baseline and12 weeks after the end of treatment, and any effect of these changes on the response to treatment was studied.
Our study has found that the sofosbuvir/daclatasvir (SOF/DAC) based therapy continues to show a high degree of effectiveness in the treatment of CHC GT4.High SVR ameliorates the predictive effect of metabolic factors as insulin resistance (IR). A significant decrease in HOMA-IR, random blood sugar(RBS)(P value<0.005) was detected 12 weeks after treatment. Also, a significant increase in total cholesterol, HDL, Triglycerides, LDL and OX LDL (P value<0.005) was detected 12 weeks after treatment.
Statistically we cannot find a significant relations between sonographic picture of liver and (HCV-PCR, HOMA-IR, OX LDL) before and after treatment.
The lipid changes in this study were interesting to the extent that long-term follow-up is strongly warranted for a better clarification of the possible role of CHC and treatment with direct acting antivirals agents(DAAs) as a potential risk for cardiovascular diseases (CVD) suggesting the potential benefit of statin co-administration during or immediately after DAAs therapy.